Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-0689-2019Class II

VITROS NT-proBNP Reagent, Cat No. 6802156

Ortho-Clinical Diagnostics, Inc. / initiated 2018-11-01 / Open, Classified / root cause: design

ORTHO-CLINICAL DIAGNOSTICS began a recall of VITROS NT-proBNP Reagent, Cat No. 6802156 Product Usage: For in vitro diagnostic use only. For the quantitative measurement of N-terminal pro Brain Natriuretic... on . FDA classified it as Class II and gives the reason as "The firm is extending their previous July 2018 recall to include additional product codes. Biased results may occur for these additional products at biotin concentrations which are lower than indicated in the current...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as design.

Recall record

Recall number
Z-0689-2019
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Ortho-Clinical Diagnostics, Inc.
Product
VITROS NT-proBNP Reagent, Cat No. 6802156 Product Usage: For in vitro diagnostic use only. For the quantitative measurement of N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in human serum and plasma (EDTA or heparin) using the VITROS ECi/ECiQ Immunodiagnostic Systems, the VITROS 3600 Immunodiagnostic System and the VITROS 5600 Integrated System to aid in the diagnosis of congestive heart failure and for the risk stratification of acute coronary syndrome and congestive heart failure. The test is further indicated as an aid in the assessment of increased risk of cardiovascular events and mortality in patients at risk for heart failure who have stable coronary artery disease. The test can also be used in the assessment of heart failure severity in patients diagnosed with congestive heart failure.
Product code
NBC Test, Natriuretic Peptide
Reason for recall
The firm is extending their previous July 2018 recall to include additional product codes. Biased results may occur for these additional products at biotin concentrations which are lower than indicated in the current Instructions for Use.
Root cause tag
design
FDA root cause
Device Design
Action
On November 1, 2018, a customer letter was sent via FedEx overnight courier and/ or ORTHO PLUS e-Communications and/ or US Postal Service Priority Mail to all customers who could process the affected products to inform them of the potential interference of biotin at levels lower than stated in the IFUs and that Ortho is in the process of revising the IFUs for the affected products. Ortho recommended customers follow normal laboratory procedures for troubleshooting of samples containing other assay interferences and it was acceptable to continue using the affected products. If you have questions, please contact Ortho Care Technical Solutions Center at 1-800-421-3311.
Quantity in commerce
46598 total, 46062 units in US (100 tests per unit)
Distribution
Worldwide Distribution - US Nationwide domestic distribution. International distribution to Australia, Belgium, Bermuda, Brazil, Canada, Chile, China, Colombia, Denmark, India, France, Japan, Germany, Italy, Mexico, Norway, Poland, Portugal, Russia, Singapore, Spain, Sweden, The Netherlands, and United Kingdom.
Product codes and lots
All expired, in-date, and future lots released.

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-0689-2019
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-0687-2019Class IIOngoingVoluntary: Firm initiated
Z-0688-2019Class IIOngoingVoluntary: Firm initiated
Z-0689-2019Class IIOngoingVoluntary: Firm initiated